Dr Paolo Ghia talks to ecancer about the phase 2 CAPTIVATE study.

It demonstrated that first-line treatment with ibrutinib and venetoclax in CLL/SLL patients provided a 5-year progression-free survival rate of 67% and overall survival rate of 96%.

Higher progression-free survival was seen in patients with undetectable minimal residual disease.

Patients with high-risk genomic features had varied progression-free survival rates, with 41% for those with del(17p)/mutated TP53.

Retreatment with ibrutinib alone or with venetoclax showed promising response rates (86% and 71%, respectively).

The combination therapy offers durable benefits, especially for high-risk patients.